Virax Biolabs (VRAX) Shares Outstanding (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Shares Outstanding (Entity) of $397590.0 for Q1 2026, up 128.92% year-over-year from $173678.0 in Q1 2025, and up 128.92% quarter-over-quarter from $173678.0 in Q1 2025.
Virax Biolabs (VRAX) Shares Outstanding (2021 - 2026) Analysis & Trends
Virax Biolabs' Shares Outstanding (Entity) history runs 6 years deep, the most recent figure standing at $397590.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 128.92% year-over-year to $397590.0; the TTM figure through Mar 2026 stood at $397590.0 (up 128.92% YoY), while the FY2026 annual figure was $397590.0, up 128.92% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $397590.0, up from $173678.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $397590.0 in Q1 2026, with the low at $10203.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $102199.5 (2024), against an average of $138064.8.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) soared 61.29% in 2022, then surged 316.73% in 2023.
- Virax Biolabs' Shares Outstanding (Entity) stood at $10203.0 in 2022, then soared by 316.73% to $42519.0 in 2023, then jumped by 191.97% to $124142.0 in 2024, then jumped by 39.9% to $173678.0 in 2025, then jumped by 128.92% to $397590.0 in 2026.
- Business Quant data shows VRAX's Shares Outstanding (Entity) at $397590.0 in Q1 2026, $173678.0 in Q1 2025, and $124142.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | 397,590.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 397,590.00 |
| Mar 31, 2025 | 149,214.00 |
| Sep 30, 2024 | 124,142.00 |
| Mar 31, 2024 | 80,257.00 |
| Mar 31, 2023 | 42,519.00 |
| Mar 31, 2022 | 10,203.00 |
| Mar 31, 2021 | 6,326.00 |